<< Back
Mar 21, 2019

Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019

SAN DIEGO, March 21, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial results for the three and 12 months ended December 31, 2018, after the market closes on Thursday, March 28, 2019. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Biocept Logo (PRNewsFoto/Biocept, Inc.)

Individuals interested in participating on the conference call may do so by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4109 for other international callers. Those interested in listening to a webcast of the live conference call may do so by visiting https://www.webcaster4.com/Webcast/Page/1271/29456.

A replay of the conference call will be available for 48 hours following the conclusion of the call by dialing (877) 344-7529 for domestic callers, (855) 669-9658 for Canadian callers, or (412) 317-0088 for other international callers, and entering the replay access code 10128915. A webcast replay will be available for 90 days at http://ir.biocept.com/events.cfm.

About Biocept 
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Investor Contact
LHA Investor Relations 
Jody Cain


Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-release-2018-fourth-quarter-and-full-year-financial-results-and-host-investor-conference-call-on-march-28-2019-300816225.html

SOURCE Biocept, Inc.